Determining treatment sensitivity in B cell lymphoma by novel microfluidics-based NK cell immunogenicity platform
Determining treatment sensitivity in B cell lymphoma by novel microfluidics-based NK cell immunogenicity platform
批准号:
9919540
负责人:
Andrew M Evens
金额:
$37.93万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-05-01 至 2022-10-31
关键词:
AccountingAddressAntibodiesAntibody TherapyB lymphoid malignancyB-Cell LymphomasB-Cell NonHodgkins LymphomaBasal CellBindingBiochemicalBiologicalBiological AssayBiological AvailabilityBiomedical EngineeringBiomedical ResearchCategoriesCell CommunicationCellsCharacteristicsClassificationClinicalClinical SensitivityCollaborationsComb animal structureCommunitiesComplexDevelopmentDevicesDropsDrug ScreeningEventFDA approvedFluorescenceGenerationsHeterogeneityHyperactive behaviorImageImmuneImmune TargetingImmune responseImmunoassayImmunomodulatorsImmunotherapeutic agentImmunotherapyIndividualKineticsLinkLymphocyteLymphomaMS4A1 geneMalignant NeoplasmsMeasurementMediatingMethodsMicrofluidic MicrochipsMicrofluidicsMolecularMonitorMonoclonal AntibodiesNatural Killer CellsNon-Hodgkin&aposs LymphomaPharmaceutical PreparationsPharmacologic SubstancePhenotypePopulationResearchResearch PersonnelResistanceResolutionSiteSorting - Cell MovementSpeedSystemSystems BiologyTechniquesTechnologyTestingTherapeuticTherapeutic Human ExperimentationTimeTransducersTumor-infiltrating immune cellsbasebehavioral phenotypingbiological heterogeneitybiomaterial compatibilitycell killingchemotherapyclinical applicationclinical assay developmentexperiencehigh throughput technologyimmune functionimmunogenicityinnovationmultidisciplinarynanosystemsneoplastic cellnovelnovel drug combinationnovel strategiespersonalized medicinepredictive testresponserituximabscreeningsingle cell analysissuccesstargeted treatmenttositumomabtranscriptomicstumortumor immunology
中文摘要
摘要
B细胞非霍奇金淋巴瘤(bNHL)是最常见的淋巴瘤亚型,占美国
所有NHL bNHL通常用抗CD 20抗体(例如,利妥昔单抗)单独或与
化疗然而,目前还没有生物学方法或标记物来预测敏感性或
对利妥昔单抗(或任何其他)抗体治疗的抗性。抗体活性的一个关键特征是通过天然的
杀伤(NK)细胞介导的抗体包被的靶肿瘤细胞的杀伤,然而,
阻力,知之甚少。在这个应用中,我们建议开发和验证高通量液滴
基于微流控平台,研究NK细胞与快速、缓慢或失活相关的关键特征,
NHL中的肿瘤杀伤动力学。我们将首先采用一种新的方法,
在微滴微阵列形成过程中使用微滴分选器以确定免疫靶细胞的表型
微流体液滴中的相互作用。我们将验证基于液滴的微流控装置来询问单细胞
完整液滴内的动态响应和细胞-细胞相互作用。接下来,我们将展示一种高纯度的
(>95%)、高通量(> 10,000个事件/秒)、四通道声流液滴分选仪,可与液滴分选仪集成
分析数组在建立相互作用的动力学曲线后,下游4通道分选将允许,
将含有活性淋巴细胞的液滴识别并分类到一个独特的池中;分离基底淋巴细胞
根据荧光的不同将其放入另一个水池。基于成像分析选择分类标准的独特功能
可以通过液滴成像阵列和声流液滴分选器的组合来提供,
这对于常规的荧光激活液滴分选器(FADS)是不可实现的,因为成像跟踪固有地
在高速水流中很棘手因此,我们的方法是一种“自下而上”的分类方法,首先确定
不同的功能类别,然后探测各个单元格类别的内容以确定键
与靶细胞杀伤相关的NK细胞的异质性免疫功能的分子分类的因素。
此外,我们将鉴定NK细胞的异质性和生物功能特性,以发现新的药物
本发明涉及通过集成的声流体液滴分选平台用于NK细胞依赖性免疫疗法的组合。我们
将证明我们的设备表型鉴定的准确性及其临床适用性
通过在单克隆抗体存在下监测和分类NK/NHL单细胞相互作用,
抗体,并从“高活性”、“基础”和无应答池进行生物化学分泌组测定。
通过将这些发现与药物筛选和表型改变药物的鉴定相结合,我们将
证明了该技术在个性化医疗和合理临床应用中的适用性,
免疫学应用。我们设想我们的平台可以用于各种单细胞分析
它将为生物工程,生物医学和治疗提供高价值
研究社区。
英文摘要
Abstract
B cell non-Hodgkin lymphomas (bNHL) are the most common lymphoma subtype representing >85% of
all NHLs. bNHL are typically treated the anti-CD20 antibody (e.g., rituximab) alone or in combination with
chemotherapy. There are currently, however, no biological methods or markers to predict the sensitivity or
resistance to rituximab (or any other) antibody therapy. A key feature of antibody activity occurs through natural
killer (NK) cell-mediated killing of antibody-coated target tumor cells, however, antitumor activity and subsequent
resistance, is poorly understood. In this application, we propose to develop and validate a high throughput droplet
based microfluidic platform to investigate the key features of NK cells associated with rapid, slow or inactive
tumor killing kinetics in NHL. We will first adapt a novel approach and integrate the biocompatible acoustofluidic
droplet sorter during the droplet microarray formation to determine the phenotypes of immune-target cell
interaction in microfluidic droplets. We will validate a droplet-based microfluidic device to interrogate single-cell
dynamic responses and cell-cell interactions within intact droplets. Next, we will demonstrate a high-purity
(>95%), high-throughput (>10,000 events/s), four-channel acoustofluidic droplet sorter to integrate with droplet
analysis array. The downstream 4-channel sorting will allow, after establishing the kinetic profiles of interactions,
to identify and sort droplets containing active lymphocytes into a distinctive pool; separate basal lymphocytes
into another pool based on fluorescence. A unique function of selecting sorting criteria based on imaging analysis
can be provided by the combination of droplet imaging array and acoustofluidic droplet sorters, which is
unachievable for conventional fluorescence activated droplet sorters (FADS) since imaging tracking is inherently
tricky in high-speed flow. Thus, our approach serves as a “bottom-up” method of classification, by first identifying
distinct functional categories and then probing the content of the individual cell category to determine the key
factors for the molecular classification of heterogeneous immune functions of NK cells related to target cell kill.
In addition, we will identify NK cell heterogeneity and bio-functional characteristics to discover novel drug
combinations for NK cell dependent immunotherapy via an integrated acoustofluidic droplet sorting platform. We
will demonstrate that the accuracy of phenotype identification of our device and its suitability for clinical
applications by monitoring and classifying NK/NHL single cell interactions in the presence of monoclonal
antibodies and performing biochemical secretome assay from ‘hyperactive’, ‘basal’ and non-responsive pools.
By combing these findings with drug screening and identification of phenotype altering drugs, we will
demonstrate the applicability of this technology for personalized medicine and rational clinical
immunotherapeutic applications. We envision our platform may be leveraged in a variety of single-cell analysis
applications in immunotherapy and it will provide high value to the bioengineering, biomedical, and therapeutic
research communities.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Modeling Multi-Source Data in Hodgkin Lymphoma
-
批准号:10579326
-
项目类别:
-
资助金额:$80.82万
-
财政年份:2022
-
负责人:Andrew M Evens
-
依托单位:
Modeling Multi-Source Data in Hodgkin Lymphoma
-
批准号:10441776
-
项目类别:
-
资助金额:$82.71万
-
财政年份:2022
-
负责人:Andrew M Evens
-
依托单位:
MAP Kinase Signaling in Lymphoma: A Novel Therapeutic Paradigm
-
批准号:8373276
-
项目类别:
-
资助金额:$37.35万
-
财政年份:2012
-
负责人:Andrew M Evens
-
依托单位:
MAP Kinase Signaling in Lymphoma: A Novel Therapeutic Paradigm
-
批准号:8814762
-
项目类别:
-
资助金额:$31.14万
-
财政年份:2012
-
负责人:Andrew M Evens
-
依托单位:
MAP Kinase Signaling in Lymphoma: A Novel Therapeutic Paradigm
-
批准号:8528522
-
项目类别:
-
资助金额:$1.69万
-
财政年份:2012
-
负责人:Andrew M Evens
-
依托单位:
MAP Kinase Signaling in Lymphoma: A Novel Therapeutic Paradigm
-
批准号:8680184
-
项目类别:
-
资助金额:$33.6万
-
财政年份:2012
-
负责人:Andrew M Evens
-
依托单位:
NU 02H8: A PHASE I TRIAL OF REDOX REGULATION IN PATIENTS WITH RELAPSED NHL
-
批准号:7604257
-
项目类别:
-
资助金额:$12.52万
-
财政年份:2006
-
负责人:Andrew M Evens
-
依托单位:
NU 02H8: A PHASE I TRIAL OF REDOX REGULATION IN PATIENTS WITH RELAPSED NHL
-
批准号:7376849
-
项目类别:
-
资助金额:$10.14万
-
财政年份:2005
-
负责人:Andrew M Evens
-
依托单位:
Targeting the Mitochondria to Treat Lymphoma and Myeloma
-
批准号:7075323
-
项目类别:
-
资助金额:$13.15万
-
财政年份:2005
-
负责人:Andrew M Evens
-
依托单位:
Targeting the Mitochondria to Treat Lymphoma and Myeloma
-
批准号:7455834
-
项目类别:
-
资助金额:$13.15万
-
财政年份:2005
-
负责人:Andrew M Evens
-
依托单位:
Targeting the Mitochondria to Treat Lymphoma and Myeloma
-
批准号:7630426
-
项目类别:
-
资助金额:$13.14万
-
财政年份:2005
-
负责人:Andrew M Evens
-
依托单位:
Targeting the Mitochondria to Treat Lymphoma and Myeloma
-
批准号:6927546
-
项目类别:
-
资助金额:$13.15万
-
财政年份:2005
-
负责人:Andrew M Evens
-
依托单位:
NU 02H8: A PHASE I TRIAL OF REDOX REGULATION IN PATIENTS WITH RELAPSED NHL
-
批准号:7200454
-
项目类别:
-
资助金额:$2.21万
-
财政年份:2004
-
负责人:Andrew M Evens
-
依托单位:
NU 02H8: A Phase I Trial of Redox Regulation in Patients with Relapsed NHL
-
批准号:7040393
-
项目类别:
-
资助金额:$1.37万
-
财政年份:2003
-
负责人:Andrew M Evens
-
依托单位:
Research Training in Oncology
-
批准号:8516463
-
项目类别:
-
资助金额:$25.32万
-
财政年份:1981
-
负责人:Andrew M Evens
-
依托单位:
海外基金